Indivior

INDV

Market cap $3.14B

Rapid induction with SUBLOCADE® showed higher treatment retention rates compared to standard induction, particularly among fentanyl-positive participants RICHMOND, Va. , Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open.

Indivior , said on Wednesday it plans to relocate its corporate domicile from the UK to the United States, establishing a new Delaware-based parent company, just months after the pharmaceutical firm moved its primary listing to New York.

RICHMOND, Va. , Oct. 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) ("Indivior PLC" or the "Company") today announced that it intends to pursue a change in domicile from the U.K. to the U.S. and will establish a new U.S. parent company, Indivior Pharmaceuticals, Inc. (IPI), above its existing U.K. parent company.

Does Indivior PLC (INDV) have what it takes to be a top stock pick for momentum investors? Let's find out.

Indivior PLC (NASDAQ:INDV ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Joseph Ciaffoni - CEO & Director Ryan Preblick - Chief Financial Officer Conference Call Participants Thibault Boutherin - Morgan Stanley, Research Division Presentation Thibault Boutherin Equity Analyst I think we start. Good morning, everyone.

RICHMOND, Va. , Aug. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events: Morgan Stanley 23rd Annual Global Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Monday, September 8 th.

Indivior's turnaround is driven by SUBLOCADE's strong growth, improved cash flow, and a three-phase recovery plan that the market undervalues. Q2 2025 results beat expectations, with SUBLOCADE delivering 9% YoY growth and management raising full-year revenue and EBITDA guidance. Key risks include heavy reliance on SUBLOCADE, legacy product erosion, and execution risk as the company transitions and optimizes operations.

Indivior (INDV) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

FFIV, INDV and NVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 5, 2025.

ARMN, QUAD, NVST, INDV and BJRI have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2025.